Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -11.71 Million USD | 57.61% |
| 2021 | -27.63 Million USD | -172.11% |
| 2020 | -10.15 Million USD | -277.55% |
| 2019 | -2.68 Million USD | -292.14% |
| 2018 | -685.96 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -2.67 Million USD | -45.96% |
| 2023 Q2 | -2.61 Billion USD | -97545.11% |
| 2022 FY | -11.71 Million USD | 57.61% |
| 2022 Q4 | -1.83 Million USD | 3.3% |
| 2022 Q3 | -1.89 Million USD | 42.81% |
| 2022 Q2 | -3.31 Million USD | 28.78% |
| 2022 Q1 | -4.66 Million USD | 28.5% |
| 2021 Q3 | -2.75 Million USD | 81.94% |
| 2021 FY | -27.63 Million USD | -172.11% |
| 2021 Q1 | -3.07 Million USD | -330.36% |
| 2021 Q2 | -15.28 Million USD | -397.27% |
| 2021 Q4 | -6.51 Million USD | -136.2% |
| 2020 Q4 | -714.12 Thousand USD | 18.43% |
| 2020 Q1 | -619.24 Thousand USD | 35.76% |
| 2020 Q2 | -7.94 Million USD | -1183.07% |
| 2020 FY | -10.15 Million USD | -277.55% |
| 2020 Q3 | -875.46 Thousand USD | 88.98% |
| 2019 Q4 | -963.88 Thousand USD | -20.91% |
| 2019 FY | -2.68 Million USD | -292.14% |
| 2019 Q3 | -797.22 Thousand USD | -82.35% |
| 2019 Q2 | -437.18 Thousand USD | 11.08% |
| 2019 Q1 | -491.65 Thousand USD | 0.0% |
| 2018 Q1 | -122.48 Thousand USD | 0.0% |
| 2018 Q2 | -152.22 Thousand USD | -24.28% |
| 2018 FY | -685.96 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -2277.96% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -23.081% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 60.941% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 82.552% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 26.056% |
| Better Therapeutics, Inc. | -38.26 Million USD | 69.382% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 72.156% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 2.131% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 65.386% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 65.964% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 89.199% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -481.585% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 65.547% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 75.049% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -756.735% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 41.247% |
| Molecular Templates, Inc. | -10.46 Million USD | -11.933% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 16.625% |
| NexImmune, Inc. | -29.19 Million USD | 59.87% |
| Orgenesis Inc. | -53.63 Million USD | 78.159% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 77.161% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -14915.8% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 27.441% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 97.677% |
| Statera Biopharma, Inc. | -98.34 Million USD | 88.088% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -69.83% |
| Trevena, Inc. | -35.28 Million USD | 66.802% |
| Vaxxinity, Inc. | -58.28 Million USD | 79.901% |
| Vaccinex, Inc. | -22.88 Million USD | 48.81% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1018.923% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 76.891% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -61.295% |